X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Annamycin is a next-generation anthracycline, which is being evaluated in combination with cytarabine for the treatment of subjects with acute myeloid leukemia.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
Liposomal-Annamycin is a Topoisomerase II inhibitor small molecule drug which is currently being evaluated in phase 1/2 clinical trials in combination with Cytarabine for the treatment of Acute Myeloid Leukemia.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
AnnAraC (annamycin), is a next-generation anthracycline, topioisomerase II inhibitor, designed to avoid multidrug resistance mechanisms and to have little to no cardiotoxicity. It is being investigated for soft tissue sarcoma and AML.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: AnnAraC
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Ara-C (Annamycin) forms complexes with DNA by intercalation between base pairs and inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex. It is being developed in combination with cytarabine for AML and soft tissue sarcoma lung metastases.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Ara-C
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
AnnAraC (annamycin), is a next-generation anthracycline, topioisomerase II inhibitor, designed to avoid multidrug resistance mechanisms and to have little to no cardiotoxicity. It is being investigated for soft tissue sarcoma.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: AnnAraC
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Annamycin forms complexes with DNA by intercalation between base pairs and inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex. It is being developed in combination with cytarabine for AML and soft tissue sarcoma lung metastases..
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Annamycin forms complexes with DNA by intercalation between base pairs and inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex. It is being developed in combination with cytarabine for AML.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Annamycin is the Company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
The delay correlated with 272% extension of survival in the group receiving 6 mg/kg Annamycin [median survival (MS) 79d for treated vs 29d vehicle, p<0.0001] and 234% for the animals dosed with Annamycin at 4 mg/kg [MS 68d, p=0.0012].
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Annamycin is the Company's next-generation anthracycline that has demonstrated a lack of cardiotoxicity in recently conducted human clinical trials for the treatment of AML.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2021
Details:
Annamycin is the Company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
The Phase 1b/2 study is a a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum- tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) and safety of Annamycin.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021
Details:
Annamycin is a "next generation" anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on doxorubicin.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Polish National Center for Research and Development
Deal Size: $6.7 million Upfront Cash: Undisclosed
Deal Type: Funding May 11, 2021
Details:
WPD entered into the amendment of its February 2019 sublicense from Moleculin of certain IP rights, including the rights to Annamycin, WP1066 and WP1122 portfolios to research, develop, manufacture, use, import, offer and sell products derived from these portfolios.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: WPD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 30, 2021
Details:
Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. Annamycin has also demonstrated a lack of cardiotoxicity in recently conducted human clinical trials for AML.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: L-ANN
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: WPD Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
Funding will support a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: L-ANN
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Agencja Badań Medycznych
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding February 08, 2021
Details:
A preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
Catalyst Clinical Research will manage Moleculin's US clinical trial to study the ability of Annamycin to treat soft tissue sarcoma (STS) that has metastasized to the lungs.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: L-ANN
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Moleculin Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 01, 2021
Details:
For animals treated with the combination of Annamycin and Ara-C, median survival ranged from 56 to 76 days, thus expanding median survival by 585%, with some animals being completely cured.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: L-ANN
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Annamycin demonstrated up to 30-fold greater concentration in lungs of Annamycin than the current standard of care drug; enables targeting cancer in its sanctuary site.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
A poster presentation entitled provided an overview of data demonstrating that uniquely high uptake and retention of Annamycin in the lungs results in consistently high in vivo activity against wide range of lung-localized tumors in mice.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
Moleculin has submitted requests to Polish regulatory authorities for approval to open two additional clinical sites for its Phase 1/2 clinical study of Annamycin for the treatment of acute myeloid leukemia (AML).
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
The US Phase 1 trial shows the safety of Annamycin in a phase I trial setting when delivered to patients at or below the lifetime maximum anthracycline dose established by the FDA.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
Moleculin has received an independent assessment of the absence of cardiotoxicity in patients treated with Annamycin in both its US and European open label and single arm Phase 1 clinical trials.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
Details:
The US Phase 1 trial met its primary endpoint, demonstrating the safety of Annamycin in treating AML when delivered to patients at or below the lifetime maximum anthracycline dose established by FDA.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
